NCAM1 and myeloid sarcoma: The quantification of T cell populations conveying the NKR CD56, CD161, and CD94 in peripheral blood of MS patients revealed that CD161+ T cells and CD94+ T cells were dramatically reduced in PPMS and SPMS individuals, while CD56+ T cells remained relatively stable in number [317].